NERV

+ Watchlist + Portfolio

Minerva Neurosciences, Inc

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.23
52-Week Range: $2.08 – $12.46
Market Cap: $156.61M
P/E (TTM): —
EPS (TTM): -36.12
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -28.42%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 20.14
Debt/Equity: —
Total Debt: $60.00M
Free Cash Flow: $-8.86M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $153.09M

NERV Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$14.65M	$12.71M	$11.90M	$5.76M
Selling, General & Admin	$10.58M	$10.41M	$9.95M	$9.34M
Operating Expenses	$25.23M	$23.12M	$21.85M	$15.10M
Operating Income	-$25.23M	-$23.12M	-$21.85M	-$15.10M
EBITDA	-$24.69M	-$21.69M	$6.02M	-$293.42M
Pretax Income	-$32.11M	-$30.01M	$1.44M	-$293.42M
Income Tax	$0.00	—	—	—
Net Income	-$32.11M	-$30.01M	$1.44M	-$293.42M
Diluted EPS	-6.01	-4.61	0.19	-34.67
Diluted Shares	5.34M	6.51M	7.57M	8.46M

NERV Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$36.09M	$40.91M	$21.36M	$82.30M
Current Assets	$40.16M	$42.00M	$22.27M	$83.10M
Total Assets	$55.09M	$56.90M	$37.14M	$97.97M
Current Liabilities	$1.38M	$3.34M	$2.84M	$2.29M
Total Liabilities	$75.11M	$85.36M	$62.84M	$238.72M
Retained Earnings	-$366.81M	-$396.82M	-$395.38M	-$688.80M
Shareholders' Equity	-$20.02M	-$28.46M	-$25.69M	-$140.75M
Working Capital	$38.78M	$38.66M	$19.43M	$80.81M

NERV Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$24.65M	-$14.78M	-$19.55M	-$13.51M
Capital Expenditure	-$16.33K	—	—	—
Free Cash Flow	-$24.66M	-$14.78M	-$19.55M	-$13.51M
Depreciation & Amortisation	$8.51K	$30.98K	$22.47K	$5.44K
Stock-Based Compensation	$4.11M	$1.97M	$1.33M	$1.33M
Investing Cash Flow	-$16.33K	$0.00	$0.00	$0.00
Financing Cash Flow	-$5.00	$19.60M	$0.00	$74.45M
Net Change in Cash	-$24.66M	$4.82M	-$19.55M	$60.94M

NERV Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.36M	$1.30M	$925.38K	$2.17M	$5.25M	$7.19M
Selling, General & Admin	$2.54M	$2.08M	$1.92M	$2.81M	$11.42M	$3.45M
Operating Expenses	$3.90M	$3.37M	$2.84M	$4.98M	$16.67M	$10.64M
Operating Income	-$3.90M	-$3.37M	-$2.84M	-$4.98M	-$16.67M	-$10.64M
EBITDA	-$3.90M	-$3.37M	-$2.74M	-$283.67M	-$16.67M	-$10.64M
Pretax Income	-$3.75M	-$3.26M	-$2.74M	-$283.67M	-$125.40M	$17.47M
Net Income	-$3.75M	-$3.26M	-$2.74M	-$283.67M	-$125.40M	$17.47M
Diluted EPS	-0.50	-0.43	-0.36	-25.51	-2.86	-0.14
Diluted Shares	7.57M	7.57M	7.57M	11.12M	43.90M	79.10M

NERV Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$17.29M	$15.25M	$12.29M	$82.30M	$32.66M	$24.65M
Current Assets	$17.92M	$15.55M	$13.02M	$83.10M	$79.11M	$79.73M
Total Assets	$32.80M	$30.42M	$28.09M	$97.97M	$94.03M	$95.09M
Current Liabilities	$1.95M	$2.53M	$2.67M	$2.29M	$4.48M	$3.96M
Total Liabilities	$61.95M	$62.53M	$62.67M	$238.72M	$348.04M	$308.39M
Retained Earnings	-$399.13M	-$402.39M	-$405.13M	-$688.80M	-$814.20M	-$796.74M
Shareholders' Equity	-$29.15M	-$32.11M	-$34.58M	-$140.75M	-$254.01M	-$213.30M
Working Capital	$15.98M	$13.02M	$10.35M	$80.81M	$74.62M	$75.77M

NERV Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$4.07M	-$2.04M	-$2.92M	-$4.48M	-$5.43M	-$13.34M
Free Cash Flow	-$4.07M	-$2.04M	-$2.92M	-$4.48M	-$5.43M	-$13.34M
Depreciation & Amortisation	$1.36K	$1.36K	$1.36K	$1.36K	$0.00	$0.00
Stock-Based Compensation	$297.23K	$298.22K	$272.90K	$459.03K	$8.71M	$2.27M
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00	-$45.29M	-$4.83M
Financing Cash Flow	$0.00	$0.00	-$45.17K	$74.50M	$1.08M	$10.17M
Net Change in Cash	-$4.07M	-$2.04M	-$2.96M	$70.02M	-$49.64M	-$8.01M

Market Snapshot

About

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders. The company focuses on treatments for schizophrenia, insomnia, depression, and Parkinson disease.